American College of Radiology
ACR Appropriateness Criteria®

Clinical Condition: Radiographically Detected Solitary Pulmonary Nodule

**Variant 1:** Solid nodule ≥1 cm, low clinical suspicion for cancer.

<table>
<thead>
<tr>
<th>Radiologic Procedure</th>
<th>Rating</th>
<th>Comments</th>
<th>RRL*</th>
</tr>
</thead>
<tbody>
<tr>
<td>CT chest without IV contrast</td>
<td>8</td>
<td>To detect occult calcifications, fat, bronchus sign, etc.</td>
<td>☢☢☢</td>
</tr>
<tr>
<td>FDG-PET/CT whole body</td>
<td>8</td>
<td>If nodule is indeterminate on HRCT.</td>
<td>☢☢☢☢</td>
</tr>
<tr>
<td>Transthoracic needle biopsy</td>
<td>8</td>
<td>If nodule shows contrast enhancement or PET scan is positive.</td>
<td>Varies</td>
</tr>
<tr>
<td>CT chest with IV contrast</td>
<td>6</td>
<td>Probably not indicated if PET is performed.</td>
<td>☢☢☢</td>
</tr>
<tr>
<td>CT chest without and with IV contrast</td>
<td>6</td>
<td>Can look at washout.</td>
<td>☢☢☢</td>
</tr>
<tr>
<td>Watchful waiting with CT follow-up</td>
<td>4</td>
<td>Reasonable at short interval.</td>
<td>Varies</td>
</tr>
<tr>
<td>MRI chest without IV contrast</td>
<td>2</td>
<td>Limited data.</td>
<td>O</td>
</tr>
<tr>
<td>MRI chest without and with IV contrast</td>
<td>2</td>
<td>Limited data.</td>
<td>O</td>
</tr>
</tbody>
</table>

**Variant 2:** Solid nodule ≥1 cm, moderate to high clinical suspicion for cancer.

<table>
<thead>
<tr>
<th>Radiologic Procedure</th>
<th>Rating</th>
<th>Comments</th>
<th>RRL*</th>
</tr>
</thead>
<tbody>
<tr>
<td>CT chest without IV contrast</td>
<td>8</td>
<td>To detect occult calcifications, fat, bronchus sign, etc.</td>
<td>☢☢☢</td>
</tr>
<tr>
<td>FDG-PET/CT whole body</td>
<td>8</td>
<td>If nodule is indeterminate on HRCT.</td>
<td>☢☢☢☢</td>
</tr>
<tr>
<td>Transthoracic needle biopsy</td>
<td>8</td>
<td>If nodule shows contrast enhancement or PET scan is positive.</td>
<td>Varies</td>
</tr>
<tr>
<td>CT chest with IV contrast</td>
<td>6</td>
<td>Probably not indicated if PET is performed.</td>
<td>☢☢☢</td>
</tr>
<tr>
<td>CT chest without and with IV contrast</td>
<td>6</td>
<td>Can look at washout.</td>
<td>☢☢☢</td>
</tr>
<tr>
<td>Watchful waiting with CT follow-up</td>
<td>2</td>
<td></td>
<td>Varies</td>
</tr>
<tr>
<td>MRI chest without IV contrast</td>
<td>2</td>
<td>Limited data.</td>
<td>O</td>
</tr>
<tr>
<td>MRI chest without and with IV contrast</td>
<td>2</td>
<td>Limited data.</td>
<td>O</td>
</tr>
</tbody>
</table>

**Rating Scale:** 1,2,3 Usually not appropriate; 4,5,6 May be appropriate; 7,8,9 Usually appropriate

*Relative Radiation Level
**Clinical Condition:** Radiographically Detected Solitary Pulmonary Nodule

**Variant 3:** Solid nodule <1 cm, low clinical suspicion for cancer.

<table>
<thead>
<tr>
<th>Radiologic Procedure</th>
<th>Rating</th>
<th>Comments</th>
<th>RRL*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Watchful waiting with CT follow-up</td>
<td>8</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CT chest without IV contrast</td>
<td>7</td>
<td>☢☢☢</td>
<td></td>
</tr>
<tr>
<td>CT chest without and with IV contrast</td>
<td>5</td>
<td>Depends on size (washout study).</td>
<td>☢☢☢</td>
</tr>
<tr>
<td>CT chest with IV contrast</td>
<td>3</td>
<td>☢☢☢</td>
<td></td>
</tr>
<tr>
<td>FDG-PET/CT whole body</td>
<td>3</td>
<td>☢☢☢☢</td>
<td></td>
</tr>
<tr>
<td>Transthoracic needle biopsy</td>
<td>2</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MRI chest without IV contrast</td>
<td>2</td>
<td>Limited data.</td>
<td>O</td>
</tr>
<tr>
<td>MRI chest without and with IV contrast</td>
<td>2</td>
<td>Limited data.</td>
<td>O</td>
</tr>
</tbody>
</table>

**Rating Scale:** 1,2,3 Usually not appropriate; 4,5,6 May be appropriate; 7,8,9 Usually appropriate

*Relative Radiation Level

**Variant 4:** Solid nodule <1 cm, moderate to high clinical suspicion for cancer.

<table>
<thead>
<tr>
<th>Radiologic Procedure</th>
<th>Rating</th>
<th>Comments</th>
<th>RRL*</th>
</tr>
</thead>
<tbody>
<tr>
<td>CT chest without IV contrast</td>
<td>8</td>
<td>☢☢☢</td>
<td></td>
</tr>
<tr>
<td>Transthoracic needle biopsy</td>
<td>6</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Watchful waiting with CT follow-up</td>
<td>5</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CT chest without and with IV contrast</td>
<td>5</td>
<td>Depends on size (washout study).</td>
<td>☢☢☢</td>
</tr>
<tr>
<td>CT chest with IV contrast</td>
<td>4</td>
<td>☢☢☢</td>
<td></td>
</tr>
<tr>
<td>FDG-PET/CT whole body</td>
<td>2</td>
<td>☢☢☢☢</td>
<td></td>
</tr>
<tr>
<td>MRI chest without IV contrast</td>
<td>2</td>
<td>Limited data.</td>
<td>O</td>
</tr>
<tr>
<td>MRI chest without and with IV contrast</td>
<td>2</td>
<td>Limited data.</td>
<td>O</td>
</tr>
</tbody>
</table>

**Rating Scale:** 1,2,3 Usually not appropriate; 4,5,6 May be appropriate; 7,8,9 Usually appropriate

*Relative Radiation Level
RADIOGRAPHICALLY DETECTED SOLITARY PULMONARY NODULE

Expert Panel on Thoracic Imaging: Jeffrey P. Kanne, MD1; Leif E. Jensen, MD, MPH2; Tan-Lucien H. Mohammed, MD3; Jacobo Kirsch, MD4; Judith K. Amorosa, MD5; Kathleen Brown, MD6; Jonathan H. Chung, MD7; Debra Sue Dyer, MD8; Mark E. Ginsburg, MD9; Darel E. Heitkamp, MD10; Ella A. Kazerooni, MD11; Loren H. Ketai, MD12; J. Anthony Parker, MD, PhD13; James G. Ravenel, MD14; Anthony G. Saleh, MD15; Rakesh D. Shah, MD.16

Summary of Literature Review

Introduction/Background
The solitary pulmonary nodule is defined as a rounded opacity ≤3 cm in diameter surrounded by lung parenchyma [1]. There should be no associated abnormality, including atelectasis or hilar lymphadenopathy. This definition is based on information obtained from the chest radiograph. On computed tomography (CT), nodules are described as being solid, semisolid (mixed attenuation), or ground-glass attenuation. Pure ground-glass attenuation nodules are areas of increased lung attenuation through which normal structures such as vessels or septa remain discernible.

The incidence of solitary nodules detected by chest radiography was previously estimated to be approximately 150,000 per year in the United States [2]. However, this figure did not include the multitude of smaller nodules detected with CT. When these are included, the incidence of pulmonary nodules in the general population dramatically increases, though precise estimates are not available. Although what constitutes a small nodule is not formally established, nodules with diameters <1 cm are generally considered small. As with radiographically detected nodules, the primary aim in evaluating these smaller nodules is the ability to confirm or exclude malignancy.

Although pulmonary nodules have been studied for decades, there are few reliable characteristics to distinguish benign from malignant nodules. The only findings sufficient to preclude further evaluation are a benign pattern of calcification or stability of nodule size for over 2 years for solid pulmonary nodules. Both of these criteria have been known since the early 1950s. Recently, the radiologic-pathologic correlation of pure ground-glass attenuation nodules and mixed attenuation nodules with the histologic spectrum of pulmonary adenocarcinoma has been described [3]. While not all ground-glass attenuation nodules are malignant, they are more likely to be multiple and may demonstrate an indolent growth pattern, rendering 2-year stability inadequate to establish benignity. The likelihood of malignancy increases with nodule size, which may influence management strategy. Other nodule features such as shape, edge characteristics, cavitation, and location have not yet been found to be accurate clues for distinguishing benign from malignant nodules [4]. As a result, the majority of nodules are indeterminate.

Overview of Diagnostic Tests
A host of diagnostic tests are available to evaluate patients with solitary pulmonary nodules. It should be noted that for all of these tests, the accuracy tends to decrease with smaller nodule size. Diagnostic tests range from noninvasive decision-theoretic approaches to major surgery. It is often the role of the radiologist to suggest an appropriate management strategy.

Theoretic approaches for decision-making include the use of Bayes theorem, logistic regression models, and neural network analysis [5-8]. These approaches are useful primarily in estimating the probability of malignancy for a particular nodule. Information from the radiologic appearance of the nodule such as size, shape, and edge characteristics can be combined with clinical risk information such as age and smoking history to produce an

1Principal Author, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin. 2Research Author, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin. 3Panel Chair, Cleveland Clinic Foundation, Cleveland, Ohio. 4Panel Vice-chair, Cleveland Clinic, Weston, Florida. 5Robert Wood Johnson Medical School, New Brunswick, New Jersey. 6Ronald Regan UCLA Medical Center, Los Angeles, California. 7National Jewish Health, Denver, Colorado. 8National Jewish Health, Denver, Colorado. 9Columbia University, New York, New York, Society of Thoracic Surgeons. 10Indiana University, Indianapolis, Indiana. 11University of Michigan Medical Center, Ann Arbor, Michigan. 12University of New Mexico, Albuquerque, New Mexico. 13Beth Israel Deaconess Medical Center, Boston, Massachusetts, Society of Nuclear Medicine. 14Medical University of South Carolina, Charleston, South Carolina. 15New York Methodist Hospital, Brooklyn, New York, The American College of Chest Physicians. 16North Shore University Hospital, Manhasset, New York.

The American College of Radiology seeks and encourages collaboration with other organizations on the development of the ACR Appropriateness Criteria through society representation on expert panels. Participation by representatives from collaborating societies on the expert panel does not necessarily imply individual or society endorsement of the final document.

Reprint requests to: publications@acr.org
overall probability for malignancy. If this probability can be set sufficiently low, strategies that include observing nodules for interval change can be advocated [9]. These estimates can be combined with subsequent imaging information to further define the probability of malignancy and guide additional steps in the diagnostic workup [10].

Extensive work is now being done using advanced image processing techniques to further evaluate nodule attributes and change over time. One area of investigation includes the ability to use 3-dimensional nodule characteristics. Volumetric analysis measures growth of nodules in short time intervals, allowing for assessment of doubling time, a biologic measure of tumor aggressiveness. Changes in nodule morphology and attenuation are also being assessed [11]. Factors that affect the reproducibility of nodule volume measurement on CT include nodule size at detection, examination technique, nodule relationship to adjacent structures, underlying lung disease, and patient factors such as phase of respiration and cardiac motion [12].

Computed-aided detection (CAD) systems have been developed for lung nodule detection on CT. CAD has the potential to improve radiologists’ diagnostic confidence in detection and accuracy in distinguishing small benign nodules from malignant ones on high-resolution CT (HRCT) [13-15]. At this point, studies have shown that CAD information can be helpful in clinical practice by providing radiologists a “second opinion” [16].

**Computed Tomography**

Contrast-enhanced CT of solitary pulmonary nodules has also been used to distinguish benign from malignant nodules. Results from a large multicenter study found that contrast-enhanced CT has a sensitivity of 98% and a specificity of 58% when using a cutoff of 15 Hounsfield units for enhancement. This led the authors to conclude that absence of enhancement is a strong predictor of benignity [17]. An analysis of combined wash-in and washout characteristics at dynamic contrast-enhanced multidetector CT showed 92% accuracy for distinguishing benign from malignant nodules [18]. The extent of enhancement reflects underlying nodule angiogenesis [19]. Limitations of the technique relate to its nonspecific nature for inflammatory disease and measurement error in evaluation of small nodules. Dual-energy CT imaging has also been used in several studies to evaluate nodules with similar diagnostic accuracy [20,21]. Through postprocessing techniques, contrast-enhanced and virtual-noncontrast images are generated from a single acquisition, which may reduce patient radiation dose.

**Magnetic Resonance Imaging**

Use of magnetic resonance imaging (MRI) in evaluation of pulmonary nodules has thus far been limited. Faster imaging sequences and techniques to mitigate artifact have allowed for detection of smaller nodules (6-10 mm) with sensitivity near 95% [22]. For nodules >1 cm, contrast-enhanced dynamic MRI has shown to be comparable to CT for distinguishing benign from malignant nodules with a sensitivity of 96%, specificity of 88%, and accuracy of 92% [23-25]. The possibility of a nonionizing assessment method for nodules is attractive, especially for younger patients. However, further research and validation are required to define a place for MR in clinical practice.

**Positron Emission Tomography**

Positron emission tomography (PET) using fluorine-18-2-fluoro-2-deoxy-D-glucose (FDG) has assumed a major role in the evaluation of patients with solitary pulmonary nodules. This technique relies on measuring glucose metabolism, which has been shown to be different between benign and malignant nodules. Many studies have demonstrated the accuracy of FDG-PET in evaluating solitary pulmonary nodules [26]. The sensitivity and specificity for this technique, as reported in the literature, have ranged from 83%-97% and from 69%-100%, respectively. FDG-PET has a higher specificity and only slightly reduced sensitivity compared to nodule-enhancement CT [27]. Limitations of PET scanning include its inability to accurately characterize certain types of lesions, including low-grade adenocarcinoma and typical carcinoid tumors. It is also limited in its ability to characterize nodules <1 cm in diameter and it may give false-positive results in patients with active infections and inflammatory diseases.

**Other Diagnostic Tests**

The aggressive nature of lung cancer often compels the diagnostic evaluation to be near certainty, and consequently tests that provide pathologic material are quite useful. Currently, such diagnostic tests include transthoracic needle biopsy (TNB), bronchoscopy, video-assisted thoracoscopic surgery (VATS), and thoracotomy. The relative roles of these procedures are not well defined in existing literature, perhaps because of the lack of a defined sensitivity and specificity for the semi-invasive tests. Both TNB [28-31] and bronchoscopy
are highly dependent on nodule size and location and on the skill of the person performing the procedure. In general, TNB has a higher sensitivity and specificity than bronchoscopy, and therefore it is usually a more appropriate test in diagnosing solitary nodules. CT fluoroscopy-guided lung biopsy using an automated cutting needle provides a high degree of diagnostic accuracy, allows for the specific characterization of lung nodules, and can be performed safely with a sensitivity of 95.1%, specificity of 100%, and accuracy of 96.2% [33]. The role of TNB relative to the surgical approach depends primarily on the ability to make a benign diagnosis. If the only role of TNB is to confirm malignancy, then it only adds to the cost of the overall workup, although there can be some use in confirming malignancy before surgery, such as diagnosing small-cell carcinoma. The diagnosis of benign disease using TNB is generally divided into three broad categories: specific benign diagnosis, nonspecific benign diagnosis, and nondiagnostic biopsy.

Recent reports suggest that the number of specific benign diagnoses can be increased using core needles, although this occurs at the cost of increasing complication rates when large-caliber needles are used. In general, for benign nonspecific and nondiagnostic studies, repeat biopsy or resection is necessary [34]. Compared to thoracotomy, VATS offers the benefit of lower perioperative morbidity and decreased length of hospital stay. VATS is most successful for peripheral lesions and some central lesions in the lower lobe, and it is the surgical method of choice for diagnosis and resection of pulmonary nodules. If the nodules are too small or located too deeply to be detected thoracoscopically, preoperative CT-guided placement of a pulmonary nodule-marker system like methylene blue or wires is a safe and accurate method of localizing pulmonary nodules at thoracoscopy [35,36].

Much of the information on which guidelines are based for management of small nodules is derived from lung cancer screening. Based on a retrospective review of 2,897 baseline screening scans, initial recommendations for noncalcified nodules measuring <5 mm were to have a follow-up scan in 1 year [37]. Management recommendations for small nodules were revised by the Fleischner Society in 2005, using separate algorithms for high- and low-risk patients [38]. Subsequently, The American College of Chest Physicians published a set of 29 recommendations for the evaluation and management of small nodules, which stress inclusion of patient preference in management decisions [39].

Summary

- In view of the variety of diagnostic tests available and the variable accuracy of the different diagnostic techniques such as FDG-PET and TNB, no single algorithm for workup is generally accepted.
- Practices vary from institution to institution, likely because of the varying prevalence of lung disease in different parts of the country, varying skill levels of operators, and varying availability of equipment.

Relative Radiation Level Information

Potential adverse health effects associated with radiation exposure are an important factor to consider when selecting the appropriate imaging procedure. Because there is a wide range of radiation exposures associated with different diagnostic procedures, a relative radiation level (RRL) indication has been included for each imaging examination. The RRLs are based on effective dose, which is a radiation dose quantity that is used to estimate population total radiation risk associated with an imaging procedure. Patients in the pediatric age group are at inherently higher risk from exposure, both because of organ sensitivity and longer life expectancy (relevant to the long latency that appears to accompany radiation exposure). For these reasons, the RRL dose estimate ranges for pediatric examinations are lower as compared to those specified for adults (see Table below). Additional information regarding radiation dose assessment for imaging examinations can be found in the ACR Appropriateness Criteria® Radiation Dose Assessment Introduction document.
Relative Radiation Level Designations

<table>
<thead>
<tr>
<th>Relative Radiation Level*</th>
<th>Adult Effective Dose Estimate Range</th>
<th>Pediatric Effective Dose Estimate Range</th>
</tr>
</thead>
<tbody>
<tr>
<td>O</td>
<td>0 mSv</td>
<td>0 mSv</td>
</tr>
<tr>
<td>☢</td>
<td>&lt;0.1 mSv</td>
<td>&lt;0.03 mSv</td>
</tr>
<tr>
<td>☢☢</td>
<td>0.1-1 mSv</td>
<td>0.03-0.3 mSv</td>
</tr>
<tr>
<td>☢☢☢</td>
<td>1-10 mSv</td>
<td>0.3-3 mSv</td>
</tr>
<tr>
<td>☢☢☢☢</td>
<td>10-30 mSv</td>
<td>3-10 mSv</td>
</tr>
<tr>
<td>☢☢☢☢☢</td>
<td>30-100 mSv</td>
<td>10-30 mSv</td>
</tr>
</tbody>
</table>

*RRL assignments for some of the examinations cannot be made, because the actual patient doses in these procedures vary as a function of a number of factors (eg, region of the body exposed to ionizing radiation, the imaging guidance that is used). The RRLs for these examinations are designated as “Varies”.

**Supporting Documents**

For additional information on the Appropriateness Criteria methodology and other supporting documents go to www.acr.org/ac.

**References**


The ACR Committee on Appropriateness Criteria and its expert panels have developed criteria for determining appropriate imaging examinations for diagnosis and treatment of specified medical condition(s). These criteria are intended to guide radiologists, radiation oncologists and referring physicians in making decisions regarding radiologic imaging and treatment. Generally, the complexity and severity of a patient’s clinical condition should dictate the selection of appropriate imaging procedures or treatments. Only those examinations generally used for evaluation of the patient’s condition are ranked. Other imaging studies necessary to evaluate other co-existent diseases or other medical consequences of this condition are not considered in this document. The availability of equipment or personnel may influence the selection of appropriate imaging procedures or treatments. Imaging techniques classified as investigational by the FDA have not been considered in developing these criteria; however, study of new equipment and applications should be encouraged. The ultimate decision regarding the appropriateness of any specific radiologic examination or treatment must be made by the referring physician and radiologist in light of all the circumstances presented in an individual examination.